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Abstract
Background: Optimal antibiotic treatment strategies of Haemophilus infections are still needed. Therefore, 30-day
case fatality rate (CFR) of Haemophilus bacteremia and efficacy of various antibiotic treatment regimes were
studied.
Methods: All episodes of Haemophilus bacteremia in the former Copenhagen County during the period 2000-9
were included in the study. Clinical and biochemical findings and outcome were collected retrospectively from
medical records.
Results: 105 consecutive episodes were identified (median age: 69 years, with only 4 children <16 years), 72%
were due to non-typeable -, 16% to typeable H. influenzae, and 11% to other Haemophilus species. Pneumonia was
the most common primary focus (in 48%), and 58% of the patients had Charlson comorbidity index> 1. Definitive
antibiotic therapy was in 26 cases benzylpenicillin, in 12 cases aminopenicillins, in 50 cases cefuroxime and in 16
cases broadspectrum antibiotics, whereas 1 palliative case died without start of therapy. Whereas the use of
broadspectrum antibiotics was related to the severity of the disease (admittance to ICU, need for assisted
ventilation or hemodialysis, septic shock), no significant difference in clinical features was demonstrated for therapy
with benzylpenicillin, aminopenicillin or cefuroxime, except benzylpenicillin was rarely administered to
immunosuppressed patients. The CFR was 22% (23/105). The choice of empiric antibiotic therapy was not
significantly associated with mortality (adequate vs. inadequate treatment: 23% (21/93) vs. 17% (2/12), respectively,
P> 0.05). In contrast, definite antibiotic therapy with cefuroxime or aminopenicillins resulted in a significantly lower
CFR than treatment with benzylpenicillin (12% (6/50) or 0% (0/12) vs. 39% (10/26), respectively, Log rank test
P< 0.02). When adjustments were made for other identified risk factors in bivariate logistic regression analysis,
treatment with cefuroxime was still were found to be associated with a significantly lower CFR than for
benzylpenicillin: OR: 0.21 (0.06-0.69), P = 0.01 (hospital-acquired bacteremia), OR: 0.27 (0.08-0.91), P= 0.04
(polymicrobial episodes), OR: 0.16 (0.04-0.59), P = 0.006 (admittance at intensive care unit), OR: 0.22 (0.06-0.82),
P = 0.02 (alcohol abuse), OR: 0.15 (0.04-0.60), P = 0.008 (altered mental state), OR: 0.22 (0.07-0.71), P = 0.01
(temperature< 38 °C), OR: 0.23 (0.07-0.79), P = 0.02 (septic shock), OR: 0.21 (0.06-0.69), P = 0.01 (mechanical
ventilation).
Conclusion: Our results suggest that, after susceptibility testing, cefuroxime or aminopenicillins are preferable to
benzylpenicillins as definitive therapy for Haemophilus bacteremia.
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Background
Haemophilus bacteremia still carries a high mortality,
and clinical features such as gender, age, acquisition of
the bacteremic episode, and the focus of infection have
recently been demonstrated to be associated with an
increased risk of a fatal outcome [1]. 3rd generation
cephalosporins have been the recommended therapy for
childhood meningitis due to H. influenzae type B, be-
cause of a more rapid sterilization of the cerebrospinal
fluid than in therapy with aminopenicillins [2] or cefur-
oxime, and a better outcome of the disease with 3rd
generation cephalosporins compared to cefuroxime [3].
Less is known, however, about the influence of various
antibiotic treatment regimes on the outcome of other
Haemophilus infections including bacteremia. In Den-
mark therapy with benzylpenicillin has been recom-
mended for treatment of ampicillin-susceptible
Haemophilus infections and has been considered to be
as effective as other recommended treatment regimes
(e.g. aminopenicillins and cefuroxime). These recommen-
dations provided in some local Danish guidelines were to
our knowledge primarily based on results obtained from
time-kill experiments showing benzylpenicillin to be as ac-
tive as amoxicillin against various Haemophilus species
[4], whereas clinical studies comparing benzylpenicillin to
other recommended treatment regimes for therapy of
Haemophilus bacteremia still are lacking In addition, the
European Committee on Antimicrobial Susceptibility
Testing (EUCAST: www.eucast.org) has stated that there
still are insufficient data for H. influenzae to set clinical
breakpoints for benzylpenicillin [5]. Thus, optimal anti-
biotic treatment strategies for infections due to Haemo-
philus species are still needed.
This retrospective study aims to investigate the effi-
cacy of benzylpenicillin therapy in comparison with
cefuroxime/aminopenicillins treatment in 105 consecu-
tive episodes of bacteremia due to Haemophilus species
in the former Copenhagen County during the time
period 2000–2009.
Results
Identification of Haemophilus bacteremia episodes
108 episodes of Haemophilus bacteremia were identified
from 1 January 2000 to 31 December 2009. Three
bacteremic episodes caused by H. haemolyticus, H. para-
influenzae and H. influenzae were considered contami-
nations, because the patients had no clinical evidence of
bacteremia, and they survived without receiving any
antibiotic therapy. Two patients had two episodes of
Haemophilus bacteremia with different primary infection
foci two and five years apart, respectively. These patients
were included with both episodes. Thus the study com-
promised 105 episodes of Haemophilus bacteremia in
103 patients.
Clinical features of Haemophilus bacteremia
Clinical and demographic characteristics according to
Haemophilus grouping are shown as Additional file 1:
Table S1 to the article. Almost all cases with Haemophi-
lus bacteremia were adults (median age: 69 years (54–
79)), with only 4 children under 16 years of age. A total
of 58% of the bacteremic episodes were community-
acquired, 30% were healthcare-related and 12% were
hospital-acquired. Most bacteremic episodes were due to
non-typeable H. influenzae (72%), whereas 16% were
due to typeable H. influenzae (serotype-b (n = 11) or
serotype-f (n = 6)) and 11% due to other Haemophilus
species including H. parainfluenzae (n = 8), H. aphrophi-
lus (n = 2), H. haemolyticus (n = 1) or H. parahaemolyti-
cus (n = 1). There were 8 polymicrobial episodes, all due
to non-typeable H. influenzae, with the isolation of re-
spectively Pseudomonas aeruginosa, Klebsiella pneumo-
niae, Staphylococcus aureus/Streptococcus pneumoniae,
S. salivarius, S. anginosus (x 2), S. pneumoniae, or other
Streptococcus species. Most isolates were fully susceptible
to ampicillin, cefuroxime and ciprofloxacin. However, 12
isolates were resistant to ampicillin, 2 to cefuroxime
(minimal inhibitory concentration (MIC)= 4 and 8 mg/L),
and 1 to cefotaxime (MIC=0.25 mg/L).
A lung focus was the most common primary focus of
infection (in 48%), and these episodes were predomin-
antly due to non-typeable H. influenzae (94%). All 5 epi-
sodes with epiglottitis and 3 out of 4 meningitis episodes
were caused by typeable H. influenzae, whereas all 3 epi-
sodes of endocarditis were due to H. parainfluenzae.
The study population consisted of 44, 44 and 17 cases
with a Charlson co-morbidity index of 0, 1–2 and 3, re-
spectively. 25 patients had cancer (16 cases were haem-
atological malignancies), 11 patients had moderate to
severe renal disease, 12 had mild and 5 moderate to se-
vere liver disease, 15 patients had chronic obstructive
pulmonary disease, and 7 patients had diabetes. 22%
(23/105) of the patients were immunosuppressed, and a
significantly higher proportion of these patients had a
healthcare-related bacteremia as compared to patients
having a community-acquired bacteremia (45% (14/17)
vs. 10% (6/61), respectively, P< 0.0001). 28% (21/76) of
patients infected with non-typeable H. influenzae were
immunosuppressed, which was a higher proportion than
for typeable H. influenzae (6% (1/17)) and for other Hae-
mophilus species (8% (1/12)). A significantly higher fre-
quency of alcohol abuse was seen among patients with
hospital-acquired bacteremia as compared to patients
with community-acquired bacteremia (46% (6/13) vs.
11% (6/54), respectively, P= 0.008).
Antibiotic treatment
Empiric antibiotic therapy at time of blood culturing was
in 37 cases benzylpenicillin (15 of these in combination
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with gentamicin), in 7 cases aminopenicillins (3 of these
in combination with gentamicin), in 41 cases cefuroxime
(1 of these in combination with ampicillin, 8 with genta-
micin and 1 with ciprofloxacin), in 5 cases piperacillin-
tazobactam (3 of these in combination with gentamicin
and 2 with ciprofloxacin), in 5 cases a 3rd generation
cephalosporin (2 in combination with ampicillin), in 1
case meropenem, in 1 case ciprofloxacin, and in 1 case
gentamicin alone. Dosage of antibiotics followed local
guidelines (e.g. benzylpenicillin 1.2 g qid, ampicillin 1–
2 g qid, cefuroxime 1.5 g tid for adults except for
treatment of CNS infections and endocarditis that
were treated with higher doses). 3 patients were initially
treated with antibiotics not considered adequate (diclox-
acillin, erythromycin), whereas 4 patients did not receive
empiric antibiotic treatment. According to the suscepti-
bility testing, empiric antibiotic therapy was not consid-
ered adequate in 2 additional episodes (1 treated with
cefuroxime and 1 treated with penicillin), whereas 96
patients received adequate empiric antibiotic treatment).
Definitive antibiotic therapy chosen according to the
susceptibility testing of the pathogen was in 26 cases
benzylpenicillin (9 of these in combination with genta-
micin), in 12 cases aminopenicillins (3 of these in com-
bination with gentamicin), in 50 cases cefuroxime (10 of
these in combination with gentamicin and 1 with cipro-
floxacin), and in 15 cases broadspectrum antibiotics
(piperacillin-tazobactam (n = 7; 4 of these in combin-
ation with gentamicin and 3 with ciprofloxacin), 3rd
generation cephalosporin (n = 5), ciprofloxacin (n = 3),
meropenem (n = 1)). 1 case with inoperable mouth can-
cer, who died 6 days after blood culturing, was palliative
and did not receive any antibiotic therapy. The definitive
antibiotic therapy was changed in 42 cases, whereas it
was a continuation of the empiric antibiotic therapy in
62 cases, including the 5 cases where the patient died
before telephone contact was made by a physician of the
Department of Clinical Microbiology with the notifica-
tion of the positive blood culture and the subsequent
results of susceptibility testing. Among these 5 cases
only one case, who was treated with benzylpenicillin, did
not receive adequate definitive antibiotic therapy.
Clinical and demographic characteristics classified
according to definitive antibiotic therapy are shown in
Table 1. The use of broadspectrum antibiotics was related
to the severity of the disease and was more frequently
administered at the ICU (50% (8/16) vs. 12% (3/26) for
benzylpenicillin (P= 0.01) or 16% (8/50) for cefuroxime
(P= 0.02), respectively), to patients with septic shock (27%
vs. 0% for cefuroxime, P= 0.002), to patients with menin-
gitis (25% vs. 0% for benzylpenicillin and cefuroxime,
P= 0.02), to patients given hemodialysis (19% vs. 2% for
cefuroxime, P< 0.05) and to patients given assisted venti-
lation (38% vs. 8% for benzylpenicillin and cefuroxime,
P= 0.04). In contrast, only 1 out of 23 immunosuppressed
patients received treatment with benzylpenicillin (in com-
bination with gentamicin), which was a significant lower
proportion for benzylpenicillin as compared to treatment
with cefuroxime (4% vs. 30%, respectively, P< 0.008) and
with broadspectrum antibiotics (4% vs. 33%, respectively,
P=0.02). A higher number of polymicrobial episodes
was observed among patients treated with benzylpenicil-
lin than for treatment with cefuroxime (19% vs. 4%, re-
spectively, P= 0.04).
Mortality
The overall 30-day CFR was 22% (Non-typeable H.
influenzae (25.0%), typeable H. influenzae (12%), other
Haemophilus species (17%), see Table 2). Patients with
hospital-acquired bacteremia were more likely to die
than patients with community-acquired or healthcare-
related bacteremia (54% vs. 26% and 19%, respectively,
P< 0.01). Polymicrobial bacteremic episodes had a sig-
nificantly higher CFR than monomicrobial episodes
(38% vs. 19%, respectively, P= 0.01). Alcohol abuse
(45% vs. 17%, P= 0.01), altered mental state (63% vs.
19%, P< 0.01), body temperature< 38 °C (41% vs. 20%,
P< 0.05), admittance at intensive care unit (17% vs.
2%, P= 0.02), development of septic shock (23% vs. 4%,
P= 0.01), and need for mechanical ventilation (26% vs.
9%, P= 0.04) were all observed more frequently among
non-survivors than among survivors, respectively.
Mortality and empiric antibiotic therapy
32% (7/22) of the patients initially given benzylpenicillin
as monotherapy died, and when combined with genta-
micin, the 30-day CFR was 27% (4/15). None of the
patients receiving aminopenicillins died (0/7), whereas
19% (6/31) of the patients receiving cefuroxime as
monotherapy died, and when combined with another
antibiotic, none of the patients died (0/10). The 30-day
CFR for empiric therapy with broad-spectrum antibio-
tics was 42% (piperacillin-tazobactam: 40% (2/5), 3. gen-
eration cephalosporins: 50% (2/4), meropenem: 100%
(1/1), ciprofloxacin: 0% (0/1) and gentamicin: 0% (0/1)).
Thus, empiric antibiotic treatment with cefuroxime/
aminopenicillins resulted in a lower CFR than therapy
with benzylpenicillin (13% (6/48) vs. 30% (11/37), re-
spectively, P= 0.06) or with broadspectrum antibiotics
(13% vs. 38% (5/13), respectively, P< 0.05). 22% (2/9) of
patients not receiving adequate empiric antibiotic ther-
apy died (1 treated with benzylpenicillin, who was
infected with an ampicillin-resistant non-typeable H.
influenzae, and 1 did not receive antibiotics), whereas 21
out of 96 patients (22%) receiving adequate antibiotic
therapy died (P> 0.05). If monotherapy benzylpenicillin,
in contrast to our initial definition, was considered as an
inadequate empiric therapy, the CFR was 26% (8/30) for
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Benzylpenicillin Cefuroxime Aminopenicillins Broadspectrum
antibiotics
n = 26 n= 50 n=12 n=16
Combination therapy with gentamicin
or ciprofloxacin
34.6% (9/26) 22.0% (11/50) 25.0% (3/12) 43.8% (7/16)
Gender (female) 46.2% (12/26) 40.0% (20/50) 58.3% (7/12) 37.5% (6/16)
Age 73 (58–84) (n = 26) 69 (52–76) (n = 50) 62 (26–82) (n = 12) 68 (56–79) (n = 16)
Charlson index
Low (0) 57.7% (15/26) 36.0% (18/50) 58.3% (7/12) 25.0% (4/16)
Medium (1–2) 30.8% (8/26) 48.0% (24/50) 25.0% (3/12) 56.2% (9/16)
High (>2) 11.5% (3/26) 16.0% (8/50) 16.7% (2/12) 18.8% (3/16)
Smoking 45.8% (11/24) 49.0% (24/49) 45.5% (5/11) 43.8% (7/16)
Alcohol abuse 26.1% (6/23) 21.7% (10/46) 9.1% (1/11) 25.0% (4/16)
Immunosuppression 3.8% (1/26) d f 30.0% (15/50) 16.7% (2/12) 31.2% (5/16)
Haemophilus species
Non-typeable 69.2% (18/26) 76.0% (38/50) 75.0% (9/12) 62.5% (10/16)
Typeable 15.4% (4/26) 14.0% (7/50) 16.7% (2/12) 25.0% (4/16)
Other types 15.4% (4/26) 14.0% (7/50) 8.3% (1/12) 12.5% (2/16)
Polymicrobial bacteremia 19.2% (5/26) d 4.0% (2/50) 0% (0/12) 6.2% (1/16)
Acquisition of bacteremia
Community-acquired 65.4% (17/26) 56.0% (28/50) g 91.7% (11/12) i 31.2% (5/16)
Healthcare-related 23.1% (6/26) 34.0% (17/50) 8.3% (1/12) 43.8% (7/16)
Hospital-acquired 11.5% (3/26) 10.0% (5/50) 0% (0/12) 25.0% (4/16)
Focus of infection
Lung 38.5% (10/26) 52.0% (26/50) 58.3% (7/12) 43.8% (7/16)
Upper respiratory tract 3.8% (1/26) 6.0% (3/50) 16.7% (2/12) 0.0% (0/16)
Meningitis 0% (0/26) f 0% (0/50) h 0% (0/12) 25.0% (4/16)
Endocarditis 3.8% (1/26) 2.0% (1/50) 0% (0/12) 6.2% (1/16)
Hepato-billiary 11.5% (3/26) 8.0% (4/50) 0% (0/12) 6.2% (1/16)
Miscellaneous 11.5% (3/26) 12.0% (6/50) 16.7% (2/12) 0.0% (0/16)
Unknown 30.8% (8/26) 20.0% (10/50) 8.3% (1/12) 18.8% (3/16)
Hospital specialty
Medical department 69.2% (18/26) 70.0% (35/50) 41.7% (5/12) 75.0% (12/16)
Surgical department 26.9% (7/26) 16.0% (8/50) 8.3% (1/12) 12.5% (2/16)
Intensive care unit 0.0% (0/26) 4.0% (2/50) 16.7% (2/12) 12.5% (2/16)
Other departments b 3.8% (1/26) 10.0% (5/50) 33.3% (4/12) 0.0% (0/16)
Altered mental state 26.9% (7/26) 24.0% (12/50) 25.0% (3/12) 53.3% (8/15)
Temp. <38 °C 30.8% (8/26) 26.0% (13/50) 9.1% (1/11) 14.3% (2/14)
Mean blood pressure (mmHg) 90 (82–102) (n = 25) 91 (84–100) (n = 48) 92 (71–109) (n = 10) 94 (73–103) (n = 15)
Heart rate 100 (79–108) (n = 25) 95 (80–108) (n = 47) 105 (89–136) (n = 10) 94 (84–106) (n =15)
B-hgb (mmol/L) 6.8 (6.4-8.3) (n = 23) 7.3 (6.3-8.3) (n = 43) 7.9 (6.9-8.7) (n = 9) 7.7 (6.0-9.0) (n = 14)
B-WBC (109 cells/L) 13.3 (10.5-16.6) (n = 23) 15.5 (9.7-20.5) (n = 49) 10.6 (7.5-17.7) (n = 10) 8.2 (2.1-18.8) (n = 15)
P-creatinine (μmol/L) 79 (58–137) (n =19) 90 (62–133) (n = 43) 69 (56–99) (n = 9) 105 (71–240) (n = 14)
Abnormal liver parameters c 72.2% (13/18) 54.1% (20/37) 40.0% (2/5) 40.0% (4/10)
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inadequate therapy and 20% (15/75) for adequate therapy
(P> 0.05). The CFR was not significantly associated to
whether the patients received empiric treatment as
monotherapy or combination therapy (23% (15/65) vs.
19% (7/36), respectively, P> 0.05).
Mortality and definitive antibiotic therapy
When therapy with cefuroxime or aminopenicillins was
chosen after result of susceptibility testing, the CFR was sig-
nificantly lower than for therapy with benzylpenicillin (12%
(6/50) or 0% (0/12) vs. 39% (10/26), respectively or to ther-
apy with broadspectrum antibiotics 38% (6/16) (Log rank
test, P< 0.02, see Figure 1). The CFR was not significantly
associated with the use of mono- or combination therapy
(19% (14/74) vs. 27% (8/30), respectively, P=0.4). When
adjusting for other identified risk factors in bivariate Logis-
tic regression analysis (see Table 2), treatment with cefurox-
ime was still associated with a significantly lower CFR than
for benzylpenicillin: OR: 0.21 (0.06-0.69), P= 0.01 (hospital-
acquired bacteremia), OR: 0.27 (0.08-0.91), P< 0.04 (poly
microbial episodes), OR: 0.16 (0.04-0.59), P=0.006 (admit-
tance at intensive care unit), OR: 0.22 (0.06-0.82), P=0.02
(alcohol abuse), OR: 0.15 (0.04-0.60), P=0.008 (altered
mental state), OR: 0.22 (0.07-0.71), P= 0.01 (temperature
< 38 °C), OR: 0.23 (0.07-0.79), P=0.02 (septic shock), OR:
0.21 (0.06-0.69), P=0.01 (mechanical ventilation). Also
when adjusted for the other co-factors shown in Table 2 (e.
g. combination therapy with gentamicin/ciprofloxacin, age,
gender, Charlson index, smoking, immunosuppression,
focus of infection, type of Haemophilus species) in bivariate
analysis, treatment with benzylpenicillin was still associated
with a significantly higher CFR than therapy with cefurox-
ime/aminopenicillins (data not shown, P< 0.05). Beside
this, if all analyses were performed for H. influenzae only or
if the patient, who were treated with benzylpenicillin and
did not receive adequate definitive antibiotic therapy, was
excluded from the analyses, treatment with benzylpenicillin
was still associated with a significantly higher CFR than
treatment with cefuroxime/aminopenicillins (data not
shown, P< 0.05).
Discussion
In the present study we found that the CFR was signifi-
cantly higher when treatment with benzylpenicillin was
continued as definitive therapy after the result of sus-
ceptibility testing, when compared to treatment with
cefuroxime/aminopenicillins. When adjusting for other
identified risk factors or other co-factors in bivariate
Logistic regression analysis, a significantly higher risk of
dying was still observed after therapy with benzylpeni-
cillin as compared to cefuroxime. Moreover, empiric
treatment with cefuroxime/aminopenicillins resulted in
lower CFR compared to therapy with benzylpenicillin,
although the difference did not reach statistical signifi-
cance (P= 0.06). To our knowledge this is the first
study investigating the treatment efficacy of benzylpeni-
cillin in Haemophilus bacteremia. Given the lack of re-
search in this area, EUCAST has considered that there
are insufficient data for H. influenzae to set clinical
breakpoints for benzylpenicillin, whereas other guide-
lines until recently have suggested 1/1 mg/L (SRGA) or
1/4 mg/L (The Norwegian Working Group on Antibio-
tics (www.unn.no/afa) as the breakpoints (S≤/R>) for
benzylpenicillin [5]. Interestingly, the MIC values and
distribution for H. influenzae and H. parainfluenzae for
benzylpenicillin, aminopenicillin and cefuroxime are
comparable, and time-kill experiments have demon-
strated benzylpenicillin to be as active as amoxicillin
against various Haemophilus species [4]. In contrast,
the pharmacokinetic profile is more favorable with ami-
nopenicillins/cefuroxime than with benzylpenicillin due
to the former’s lower protein binding (17-40% vs. ~45-
65%, respectively) and longer serum elimination half-life
(T½: 1.1-1.4 vs. 0.5-0.75 hrs, respectively) (www.eucast.
org, [6,7]). Indeed, EUCAST has calculated significantly
lower target attainment rates (i.e. time above the
Table 1 Clinical characteristics of Haemophilus bacteremia according to definitive antibiotic therapya (Continued)
P-CRP (mg/L) 145 (45–214) (n = 24) d 184 (105–262) (n = 48) 186 (55–241) (n = 10) 173 (119–271) (n = 14)
Transfer to ICU 11.5% (3/26) 12.2% (6/49) h 25.0% (3/12) 37.5% (6/16)
Septic shock 11.5% (3/26) 0% (0/48) h 8.3% (1/12) 26.7% (4/15)
Mechanical ventilation 7.7% (2/26) f 8.2% (4/49) h 8.3% (1/12) 37.5% (6/16)
Hemodialysis 3.8% (1/26) 2.1% (1/48) h 0% (0/12) 18.8% (3/16)
Death 38.5% (10/26) d e 12.0% (6/50) h 0% (0/12) i 37.5% (6/16)
a) 1 pt with inoperable mouth cancer died without initiation of antibiotic therapy.
b) Paediatric, gynaecological and ear nose and throat departments.
c) Liver parameters were considered abnormal, if P-ALAT> 45 U/L, P-ASAT> 35 U/L, P-Albumin< 550 μM, P-Amylase> 120 U/L, P-Bilirubin> 22 μM or P-alkaline
phosphatase> 105 U/L.
Significant difference (Fisher exact test or Mann Whitney test, P< 0.05): benzylpenicillin vs. cefuroxime (d), benzylpenicillin vs. /aminopenicillins (e),
benzylpenicillin vs. broadspectrum antibiotics (f), cefuroxime vs. aminopenicillins (g) cefuroxime vs. broadspectrum antibiotics (h). aminopenicillins vs.
broadspectrum antibiotics (i).
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Table 2 Clinical characteristics of Haemophilus bacteremia according to 30-day CFR
Median (interquartile range) Non-survivors Survivors OR P-value
or percentage n= 23 n=82
Gender (female) 47.8% (11/23) 41.5% (34/82) 1.29 (0.51-3.28) 0.64
Age 69 (60–83) 69 (50–77) 1.03 (1.00-1.05) 0.07
0-64 years 34.8% (8/23) 46.3% (38/82) 1 (reference)
65-80 years 26.1% (6/23) 35.4% (29/82) 0.98 (0.31-3.15) 0.98
>80 years 39.1% (9/23) 18.3% (15/82) 2.85 (0.93-8.77) 0.07
Haemophilus species
Nontypeable 82.6% (19/23) 69.5% (57/82) 1 (reference)
Typeable 8.7% (2/23) 18.3% (15/82) 0.40 (0.08-1.91) 0.25
Others 8.7% (2/23) 12.2% (10/82) 0.60 (0.12-2.99) 0.53
Polymicrobial bacteremia 21.7% (5/23) 3.7% (3/82) 7.32 (1.60-33.5) 0.01
Charlson index
Low (0) 30.4% (7/23) 45.1% (37/82) 1 (reference)
Medium (1–2) 52.2% (12/23) 39.0% (32/82) 1.98 (0.70-5.64) 0.20
High (>2) 17.4% (4/23) 15.9% (13/82) 1.63 (0.41-6.47) 0.49
Smoking 50.0% (11/22) 46.8% (37/79) 1.14 (0.44-2.92) 0.81
Alcohol abuse 45.0% (9/20) 16.9% (13/77) 4.03 (1.40-11.67) 0.01
Immunosuppression 13.6% (3/22) 24.1% (20/83) 0.50 (0.13-1.86) 0.39
Focus of infection
Lung 52.2% (12/23) 46.3% (38/82) 1.29 (0.50-3.19) 0.64
Upper respiratory tract 0.0% (0/23) 7.3% (6/82) 0.25 (0.01-4.62) 0.34
Meningitis 8.7% (2/23) 2.4% (2/82) 3.81 (0.51-28.67) 0.21
Endocarditis 0.0% (0/23) 3.7% (3/82) 0.48 (0.02-9.70) >0.99
Hepato-billiary 4.3% (1/23) 9.8% (8/82) 0.42 (0.05-3.55) 0.68
Miscellaneous 4.3% (1/23) 12.2% (10/82) 0.33 (0.04-2.70) 0.45
Unknown 30.4% (7/23) 19.5% (16/82) 1.81 (0.64-5.12) 0.27
Acquisition of bacteremia
Community-acquired 43.5% (10/23) 62.2% (51/82) 1 (reference)
Healthcare-related 26.1% (6/23) 30.5% (25/82) 1.22 (0.40-3.75) 0.72
Hospital-acquired 30.4% (7/23) 7.3% (6/82) 5.95 (1.65-21.48) <0.01
Hospital specialty
Medical 56.5% (13/23) 69.5% (57/82) 1 (reference)
Surgical 21.7% (5/23) 15.9% (13/82) 1.69 (0.51-5.57) 0.39
Intensive care unit 17.4% (4/23) 2.4% (2/82) 8.78 (1.45-53.1) 0.02
Othersa 4.3% (1/23) 12.2% (10/82) 0.44 (0.05-3.73) 0.45
Altered mental state 65.2% (15/23) 18.5% (15/81) 8.25 (2.96-23.00) <0.01
Temp. <38 40.9% (9/22) 20.0% (16/80) 2.77 (1.01-7.61) <0.05
Mean blood pressure (mmHg) 97 (86–113) (n = 22) 90 (81–100) (n = 76) 1.03 (1.00-1.06) 0.15
Heart rate 100 (84–112) (n = 22) 95 (80–108) (n = 76) 1.01 (0.99-1.03) 0.46
B-hgb (mmol/L) 7.3 (6.3-9.0) (n = 21) 7.3 (6.5-8.4) (n = 69) 1.08 (0.75-1.55) 0.7
B-WBC (109 cells/L) 13.3 (11.6-17.6) (n = 23) 14.2 (8.3-20) (n = 75) 0.99 (0.93-1.05) 0.61
P-creatinine (μmol/L) 91 (61–141) (n = 21) 82 (61–120) (n = 64) 1.00 (0.99-1.01) 0.97
Abnormal liver parametersb 58.8% (10/17) 54.7% (29/53) 1.18 (0.39-3.58) >0.99
P-CRP (mg/L) 175 (96–270) (n = 21) 175 (97–257) (n = 76) 1.00 (1.00-1.01) 0.97
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minimal inhibitory concentration-target of 30-40% of the
dosing interval above MICs for susceptible H. influenzae
population) for benzylpenicillin (1.2 g qid) than for
amoxicillin (1 g qid)/cefuroxime (1.5 g tid) as determined
by Monte Carlo simulations (e.g. 46-76% vs. 100%, re-
spectively for MIC: 1–2 mg/L, T>MIC: 40%). Most
likely such less favorable pharmacodynamic properties
with benzylpenicillin therapy could potentially explain
the significantly higher CFR of Haemophilus bacteremia
with the dosing used in the present study (benzylpenicil-
lin: 1.2 g qid). Thus, our results suggest that treatment of
adults with benzylpenicillin in doses of 1.2 qid should
not be considered as therapy for Haemophilus
bacteremia, but whether higher doses of benzylpenicillin
(e.g. 2.4 g × 6 resulting in target attainment rates of 95-98
% for MIC: 1–2 mg/L, T>MIC: 40%) could be an effect-
ive treatment still remains to be evaluated.
Our study has some important limitations. Our study
was not a randomized study comparing the treatment effi-
cacy of benzylpenicillin and cefuroxime/aminopenicillins
for Haemophilus bacteremia, and the retrospective study
design could potentially have influenced the strength of
the statistical calculations due to missing values. Our data
collection, however, was almost complete regarding the
clinical characteristics and antibiotic therapy. Multivari-
able analysis for significant risk factors for progression to
death could not be performed including all the risk factors
identified in the univariate analysis, because there was a
relatively low number of outcomes compared to number
of variables included in the analysis [8]. The definitive
antibiotic therapy was therefore only adjusted for single
individual risk factors in separate bivariate analyses.
Whereas the epidemiology of Haemophilus infections
has been studied extensively since the introduction of the
Table 2 Clinical characteristics of Haemophilus bacteremia according to 30-day CFR (Continued)
Transfer to ICU 30.4% (7/23) 13.6% (11/81) 2.78 (0.93-8.30) 0.11
Shock 22.7% (5/22) 3.75% (3/80) 7.55 (1.64-34.68) 0.01
Mechanical ventilation 26.1% (6/23) 8.6% (7/81) 3.73 (1.11-12.53) 0.04
Hemodialysis 4.5% (1/22) 4.9% (4/81) 0.92 (0.10-8.64) >0.99
Inadequate empiric antibiotic therapy 8.7% (2/23) 12.2% (10/82) 0.69 (0.14-3.38) >0.99
Definitive antibiotic therapy
Benzylpenicillin 45.5% (10/22) 19.5% (16/82) 1 (reference)
Aminopenicillin 0% (0/22) 14.6% (12/82) Not determinedc <0.02d
Cefuroxime 27.2% (6/22) 53.7% (44/82) 0.22 (0.07-0.70) 0.01
Broadspectrum antibiotics 27.2% (6/22) 12.2% (10/82) 0.96 (0.27-3.47) 0.95
a) Paediatric, gynaecological and ear nose and throat departments.
b) Liver parameters were considered abnormal, if P-ALAT> 45 U/L, P-ASAT> 35 U/L, P-Albumin< 550 μM, P-Amylase> 120 U/L, P-Bilirubin> 22 μM or P-alkaline
phosphatase> 105 U/L.
c) OR could not be determined, because CFR = 0 for aminopenicillins.
d) P-value was determined by Fisher Exact test for benzylpenicillin vs. aminopenicillins.
Figure 1 Kaplan Meyer Survival curves for Haemophilus bacteremia according to definitive antibiotic therapy. Treatment with
cefuroxime or aminopenicillins resulted in a significant lower 30-day CFR than treatment with benzylpenicillin or broadspectrum antibiotics (Log
rank test, P< 0.02). When compared to benzylpenicillin, treatment with cefuroxime caused a significantly lower 30-day CFR in crude analysis (OR:
0.22 (0.07-0.70, P = 0.01), and in adjusted analyses including variables presented in table 2 (Bivariate logistic regression, P< 0.05).
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H. influenzae type b vaccine in childhood vaccination
programs [9-11] demonstrating a virtual elimination of
invasive H. influenzae type b infections [12-16], less is
known about the clinical presentation of Haemophilus
infections in the post-vaccination era. In the present
study, we found that the clinical presentation (e.g. focus
of infection) of Haemophilus bacteremia still followed
observations from the pre-vaccination period and was
closely related to the Haemophilus species. Almost all
bacteremic episodes with a lung focus were due to non-
typeable H. influenzae; meningitis and epiglottis were
primarily observed among episodes due to typeable H.
influenzae, whereas endocarditis was solely due to H.
parainfluenzae. Non-typeable H. influenzae accounted
for most of the bacteremic episodes (3 out of every 4 epi-
sodes), and in accordance with previous studies, patients
infected with non-typeable H. influenzae had an higher
age, were more often immunosuppressed, and had a high
CFR [17-20]. Almost all healthcare-related bacteremic
episodes were due to non-typeable H. influenzae,
whereas patients with typeable H. influenzae bacteremia
had the youngest median age – a relationship which has
also been demonstrated previously [20]. These patients
were more frequently transferred to an intensive care
unit and received mechanical ventilation, but had a lower
CFR than the other patient groups. This was most likely
due to a high number of patients with epiglottitis, who
all required assisted ventilation, but all survived the
bacteremic episode.
Conclusion
Our results suggest that, after susceptibility testing,
cefuroxime/aminopenicillins is preferable to benzylpeni-
cillins as definitive therapy for H. influenzae bacteremia.
Methods
Identification of bacteremic episodes
All episodes of positive blood cultures with Haemophilus
species identified at the Department of Clinical Micro-
biology during the time period 2000–2009 were included
in the study. The Department of Clinical Microbiology
provides diagnostic service for all hospitals (three public
funded university hospitals with approximately 1600
beds) and primary care in the former Copenhagen
County (approximately 620,000 inhabitants, 526 km2).
Blood culturing was performed at the attending physi-
cian’s decision comprising 1 venipuncture per episode
(40 ml of blood distributed in two aerobic and two anaer-
obic bottles for adults and 8 ml in pediatric bottles for
small children; BACTECW, Becton-Dickinson, Sparks,
MD, USA). In case of a positive blood culture, a phys-
ician of the Department of Clinical Microbiology notified
by telephone the treating physician of the patient con-
cerned, giving the results of the Gram staining and the
motility examination, and also supplying recommenda-
tions about antibiotic therapy, diagnostic and therapeutic
procedures etc. Another contact with the treating phys-
ician was made the following day to provide the results
of susceptibility testing and bacterial identification. The
positive blood culture was sub-cultured, and the identifi-
cation of the various Haemophilus strains was done using
standard methods [21]; subsequent serotyping was per-
formed using serotype-specific anti-sera and/or was tested
at the National Reference Laboratory at Statens Serum
Institut. Susceptibility testing was performed by disc diffu-
sion methods (Oxoid, Hanks, UK), according to zone
diameter break-points set out by the Swedish Reference
Group for Antibiotics (SRGA: www.srga.org). β-lactamase
production was determined by use of Cefinase™ paper discs
(Becton Dickinson, NJ, USA) to identify resistance to ben-
zylpenicillin and aminopenicillins. Cefuroxime-resistance
was confirmed by subsequent MIC determination (E-testW,
bioMérieux, Marcy l’Etoile, France).
Data collection
Clinical and laboratory information were collected retro-
spectively from medical records. Hospital admission and
discharge records including date of death were con-
firmed in the National Hospital Registration Database.
The study was approved by the Danish Data Protection
Agency (Record 2008-41-2688) and followed the guide-
lines of the local scientific committee.
Definitions
The bacteremic episode was defined as community-
acquired or hospital-acquired according to CDC criteria
[22]. In addition, a healthcare-related group was defined
for patients who had been hospitalized within 30 days
prior to the bacteremic episode, or who regularly visited
the hospital (e.g. for chemotherapy or hemodialysis) [23].
Polymicrobial episodes were defined as isolation of a sep-
arate significant agent from blood cultures within two days
of the Haemophilus bacteremic episode. Hospital depart-
ments were divided into medical -, surgical -, intensive
care unit (ICU) or other departments (e.g. pediatric, gy-
naecological and ear-nose-throat departments). The focus
of the infection was registered on the basis of clinical,
radiological and microbiological findings.
Comorbidity at time of hospitalization was assessed
for each individual patient using the Charlson comobid-
ity index scores: 0 points = low, 1–2 points =medium
and >2 = high [24]. Patients were defined as being im-
munosuppressed if they had cancer or had received im-
munosuppressive therapy. Alcohol abuse was defined as
an alcohol intake of more than 14 units per week for
women and more than 21 units per week for men.
Patients were considered to have either never smoked or
smoked at least once. Shock was registered if a patient
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had clinical evidence of shock (e.g. hypotension and tachy-
cardia) and/or received vasoactive drugs. The case fatality
rate (CFR) was defined as the all cause mortality rate
within 30 days after the positive blood culture was taken.
Empiric antibiotic therapy was considered adequate if
the patient received intravenous treatment with an anti-
biotic for which the bacterial isolate was fully susceptible,
except for ciprofloxacin, where oral therapy was also con-
sidered adequate. According to the local guidelines of the
Department of Clinical Microbiology, therapy with ben-
zylpenicillin was considered adequate for isolates suscep-
tible for ampicillin. Definitive antibiotic therapy was
defined as the antibiotic therapy administered after the
results of susceptibility testing were available. If a patient
died before susceptibility data were available, the empiric
antibiotic therapy given at time of death was also consid-
ered as definitive antibiotic therapy.
Statistics
Statistics were performed using the Statistical Package
for Social Sciences (version 16.0; SPSS, IBM). Data are
represented as medians and interquartile ranges. Com-
parison between groups was performed using the Mann
Whitney test for continuous data and the Fisher Exact
test for categorical data. Kaplan-Meyer survival curves
and the Log-rank test were performed according to de-
finitive antibiotic therapy (benzylpenicillin, cefuroxime,
aminopenicillins and broadspectrum antibiotics). Logistic
regression analysis was employed for calculating the rela-
tive risk of dying within 30 days after blood culturing.
Due to the relatively low number of fatal outcomes com-
pared to the number of variables studied, multivariable
analyses were only performed for evaluating the associ-
ation between definitive antibiotic therapy and mortality
by adjusting for confounding variables in bivariate analyses
[8]. P-value <0.05 was considered as statistically significant.
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